EQS-News

Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity 09.01.2026, 14:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: leon-nanodrugs GmbH / Key word(s): Research Update/Study results
Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity

09.01.2026 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

 

Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity

 

Planegg/Munich (Germany), January 9th, 2026 – A new study published in Pharmaceutics (https://doi.org/10.3390/pharmaceutics18010050) shows that LEON’s FR-JET® modular mixer addresses key manufacturing challenges by enabling the production of highly concentrated lipid nanoparticles (LNPs). The study demonstrates that LNP formulation at significantly higher lipid mixture concentrations, beyond those currently reported in the literature and industry sources, can improve biological function in vivo, streamline manufacturing, and improve storage stability.

Overcoming the bottleneck

There is growing recognition across the industry that LNP manufacturing challenges are not solely scientific, but are also largely operational in nature,” said Dr. Blerina Shkodra, lead author of the study. “Using LEON’s FR-JET® technology, we show that LNPs can be formulated at lipid mixture concentrations above 50 mg/mL, not only retaining product quality but also enhancing potency in vivo. These findings indicate a practical approach to simplified manufacturing and increased throughput, enabling drug innovators to bring life-saving mRNA therapies to patients faster and more efficiently.”

Traditional microfluidic mixers are frequently limited by clogging, poor robustness, and scalability barriers, while conventional T-mixers can exhibit inconsistent reproducibility often associated with scaling-out strategies that can complicate manufacturing. In contrast, LEON’s FR-JET® modular mixer delivers a robust mixing, unlocking process intensification while supporting a predictable and direct scale-up.
 

Why formulation at significantly higher lipid mixture concentrations matters for LNP developers:

Manufacturability – process intensification: Manufacturing at higher starting material concentrations can shorten, or even eliminate, the initial rate-limiting ultrafiltration step in tangential flow filtration (TFF), reducing overall downstream process time and buffer consumption during diafiltration.

Product Performance – potency and dosing: Cryogenic transmission electron microscopy (Cryo-TEM) revealed more uniform, solid-core particles. Increased lipid and RNA concentrations can enhance in vivo potency, which may translate into improved tolerability and more efficient dosing strategies.

Product Quality – morphology and stability: Higher solid-core fractions indicate more uniform particle morphologies, alongside demonstrated colloidal stability for 3 to 6 months in two different buffer systems.

CMC Scalability – development to manufacturing: This approach supports smoother translation from formulation development to manufacturing scale, enabling more robust processes and easier technology transfer.

 

This peer-reviewed study validates the science behind the FR-JET® technology and confirms that our commercially available manufacturing systems are making a big difference,” said Dr. Wolfgang Hofmann, CEO of LEON. “It marks the beginning of a new phase for LNP manufacturing, and it paves the way for what LEON has prepared to deliver in 2026.

ABOUT LEON (leon-nanodrugs GmbH)

Based in Planegg/Munich, leon-nanodrugs GmbH is a Pharmatech company specializing in the development and commercialization of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanoparticles, such as lipid nanoparticles (LNPs). The company leverages its proprietary FR-JET® technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and commercial production, and the company further supports its clients by offering formulation and process development services. LEON’s platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs to capitalize on advancements in advanced therapies.

 

For further information, please visit https://leon-nanodrugs.com/ and follow us on LinkedIn.

 

CONTACT: MEDIA INQUIRIES:
leon-nanodrugs GmbH
Maja Kuhar, Marketing Director
Phone: +49-89-41424889-98
Mail: m.kuhar@leon-nanodrugs.com
MC Services AG
Katja Arnold / Eva Bauer
Phone: +49-89-210228-0
Mail: leon-nanodrugs@mc-services.eu


09.01.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2257986  09.01.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer